Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-04
2006-04-04
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S866000, C536S122000
Reexamination Certificate
active
07022682
ABSTRACT:
The present invention provides for a method for treatment and prevention of Type II Diabetes Mellitus and its complications comprising the step of administering to a patient a therapeutically-effective amount of Rhamnan Sulphate, its functional analogs, or its physiologically acceptable salts, in therapeutic proportions. Anticoagulation activity in the blood plasma of a patient is not appreciably increased.
REFERENCES:
patent: 4758283 (1988-07-01), Takemura
patent: 5268366 (1993-12-01), Maeda
patent: 5321133 (1994-06-01), Colliec
patent: 5698534 (1997-12-01), Nagaoka
patent: 5948405 (1999-09-01), Cedro
patent: 411080003 (1999-03-01), None
Tanner, Felix C. , “Oxidized Low Density Lipoproteins inhibit Relaxations of Porcine Coronary Arteries” Circulation vol. 83, No. 6 Jun. 1991 pp. 2012-2020.
Kim, HH, etaaal. “Basic peptide system for efficient delivery of foreign genes”Biochim Biophys ActaMay 12, 2003, 1640 (2-3) pp. 129-136.
Hiraoka, Atsushi . “Capillary-Isotachophoretic Analyses of Algal Acidic Polysaccharides . . . ”Chem Pharm BullMar. 1992. vol. 40, No. 3, pp. 783-785.
Hayakawa, Yumiko. Et al. “Inhibition of Thrombin by Sulfated polysaccharides isolated from Green Algae” Biochim Biophys Acta (1543 (2000) pp. 86-94.
Petrie, Jr, et al. “Endothelial Nitric Oxide production and Insulin Sensitivity. ”Circulation. Apr. 1, 1996. vol. 93, No. 7. pp. 1331-1333.
Van Den Born, J etal. “Vessel Wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in thearat. ”Nephrol DialTTransplant1997, vol. 12 supp. 2, pp. 27-31.
Du, Xl, et al. “Hyperglycemia inhibits endothelial Nitric Oxide synthase activity by posttranslational mo Modification at the Aki site.”J Clin InvestNov. 2001 vol. 108, No. 9 pp. 1341-1348.
Minmin, C, etaal. Advanced Glycation end products induce apoptosis and procoagulant activity in culture human umbilical vein endothelial cells.Diabetes Res Clin Pract. Dec. 1999, vol. 46, No. 3 pp. 97-202.
Ebara, T, etaal . “Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.”J. Clin Invest. Jun. 2000 vol. 105, No. 12. pp. 1807-1818.
Raats, CJ, et al. “Glomerular heparan sulfate alternations mechanisms and relevance for proteinuria.”Kidney Int. Feb. 2000. vol. 57. No. 2, pp. 385-4000.
Conde-Knape K. “Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications.” Diabetes Metab Res Rev. Nov.-Dec. 2001, vol. 17, No. 6, pp. 412-421.
Yokoyama, H, etaal. “Serun and Urinary concentrations of heparan sulfate in patients with diabetic nephropathy” Kidney Int. Aug. 1999. vol. 56, No. 2 pp. 650-658.
Jensen, T. “Pathogenesis of diabetic vascular disease: evidence for teh role of reduced heparan sulfate proteoglycan.”DiabetesSep. 1997, vol. 46, supp 2 pp. S98-100.
Hayden, Melvin, et . al . Is type 2 diabetes mellitus a vascular disease with hyperglycemia a late manifestation?Cardiovascular Diabetology. Feb. 12, 2003. vol. 2, No. 2.
Yoyoneda, A, et al. “Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans.”Matrix Biol. Mar. 2003, vol. 22, No. 1 pp. 25-33.
Sai, P. et al. “Heparin attenuates low-dose streptozotocin-induced immune diabetes in mice and inhibits the beta-cell binding of T-splenocytes in vitro.”:DiabetologiaApr. 1991 vol. 34. No. 4 pp. 212-217.
Moberg L, et al. “Production of tissue factor by pancreatic islet cells asaa trigger of detrimental thrombotic reactions in clinical islet transplantation.”LanceetDec. 21, 2002. vol. 360, No. 9350. pp. 2039-2045.
Cnop, M, et al. “Low Density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification.”EndocrinologySep. 2002, vol. 143, No. 9 pp. 3449-3453.
Miller, AW, et al. “Mechanisms of Impaired Endothelial Function Associated with Insulin Resistance”J Cardiovasc Pharmacol TherApr. 1998, vol. 3, No. 2 pp. 125-134.
Sadri, P, et al. “Blockade of hepatic nitric oxide synthase causes insulin resistance”Am J PhysiolJul. 1997 vol. 277, No. 1 pt 1, pp. 101-108.
Wascher, TC, et al. “Effects of Low-dose L-arginine on insulin mediated vasodilation and insulin sensistivity”Eur J Clim InvestAug. 1997, vol. 27, No. 8, pp. 690-695.
Endomatrix, Inc.
Kamarei, Esq. Ali
White Everett
Wilson James O.
LandOfFree
Method for the treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571995